PPL Therapeutics, the Scottish biotechnology company that cloned Dolly the sheep, is returning to the equity markets after pulling a secondary offer in March.
Deutsche Bank, the company's broker, was slated to lead PPL's original offer, aiming to raise between £40m and £45m (€64m and €72m) in an open offer and international placing in Europe and the US. The company said in a statement the offer was pulled "due to prevailing uncertain worldwide stock market conditions and some misplaced fears over the risk due to the group from the foot and mouth disease outbreak."
